急性缺血性卒中静脉溶栓治疗研究进展

Advances in intravenous thrombolysis for acute ischemic stroke

卒中是导致我国居民致死、致残的第一大疾病,其中缺血性卒中约占3/4。静脉溶栓(IVT)是急性缺血性卒中(AIS)最有效的治疗措施之一,可在发病后第一时间开通闭塞的血管、恢复血流,进而最大限度地减少AIS患者残疾或死亡的发生。卒中中心建设有助于提高溶栓治疗率和溶栓质量。对于合并大血管闭塞的AIS,在常规IVT治疗的基础上桥接动脉取栓治疗,可增加患者获得良好功能结局的机会。本文总结了IVT治疗AIS的背景、我国卒中中心建设以及溶栓药物新进展,就AIS患者IVT治疗研究进展作一述评。

Stroke is the leading cause of death and disability among Chinese people,with approximately three-quarters attributed to ischemic stroke.Intravenous thrombolysis(IVT)is one of the most effective treatment for acute ischemic stroke(AIS),which can open blocked blood vessels and restore blood flow at first time after symptom onset,thereby to minimize disability or death in AIS patients.Establishing stroke centers can improve both thrombolysis rates and quality.For large vessel occlusion strokes,arterial thrombectomy following intravenous thrombolysis increases the chances of achieving favorable outcomes.In this article,we reviewed the development of IVT in AIS patients,including the background of intravenous thrombolysis,establishment of stroke center systems in China,and the latest research progress on thrombolytic drugs.